Mestre Andrea, Sathiya Narayanan Rajalakshmi, Rivas Deliana, John Jobby, Abdulqader Mohammed Ali, Khanna Tushar, Chakinala Raja Chandra, Gupta Sachin
Internal Medicine, Universidad del Rosario, Bogota, COL.
Internal Medicine, Stanley Medical College, Chennai, IND.
Cureus. 2022 Jun 30;14(6):e26463. doi: 10.7759/cureus.26463. eCollection 2022 Jun.
The global prevalence of Helicobacter pylori (H. pylori) is estimated to be around 4.4 billion, with the majority of individuals affected in developing countries. Chronic infection of the gram-negative bacterium results in several gastrointestinal pathologies such as chronic gastritis, peptic ulcer, and cancer. Probiotics compete directly with H. pylori and help restore the gut microbial environment; these living microorganisms are comparatively more effective than the standard triple antibiotic regimen in the management of symptoms related to the pathogenic bacteria. The need for alternative therapy is better explained by the increasing rate of antibiotic resistance and the lowering of patient compliance to the standard treatment. Adjuvant administration of probiotics to H. pylori eradication therapy is associated with a higher H. pylori eradication rate, decreased diarrhea-related treatment, less common self-reported side effects, and higher treatment compliance. Therefore, with the ongoing and future resistance to antibiotics, this systematic review aims to investigate the use and efficacy of probiotics when used alone or in conjunction with the current guideline treatment. A literature search was conducted using Pubmed, MEDLINE, and Cochrane for peer-reviewed articles published between January 1, 2016 and April 2022. MeSH terms used were: "H. pylori," "H. pylori and probiotics," "Probiotics," "H. pylori treatment," "Mechanism of Action" with subheadings as "clinical manifestations," "treatment," and "diagnosis." All literature reviews, original papers, and case reports were included. This search strategy aimed to find literature that could describe the transmission and mechanism of action of H. pylori, the current treatment guidelines, and the efficacy of probiotics in eradicating H. pylori.
据估计，全球幽门螺杆菌（H. pylori）感染人数约为44亿，其中大多数感染者来自发展中国家。这种革兰氏阴性菌的慢性感染会导致多种胃肠道疾病，如慢性胃炎、消化性溃疡和癌症。益生菌可直接与幽门螺杆菌竞争，并有助于恢复肠道微生物环境；在治疗与这种病原菌相关的症状方面，这些活微生物比标准三联抗生素疗法更有效。抗生素耐药率上升以及患者对标准治疗的依从性降低，更好地解释了替代疗法的必要性。在幽门螺杆菌根除治疗中辅助使用益生菌，可提高幽门螺杆菌根除率，减少与腹泻相关的治疗，减少常见的自我报告副作用，并提高治疗依从性。因此，鉴于对抗生素的持续和未来耐药性，本系统评价旨在研究单独使用或与当前指南治疗联合使用时益生菌的用途和疗效。使用Pubmed、MEDLINE和Cochrane对2016年1月1日至2022年4月发表的同行评审文章进行了文献检索。使用的医学主题词为：“幽门螺杆菌”、“幽门螺杆菌与益生菌”、“益生菌”、“幽门螺杆菌治疗”、“作用机制”，副标题为“临床表现”、“治疗”和“诊断”。纳入了所有文献综述、原创论文和病例报告。该检索策略旨在找到能够描述幽门螺杆菌的传播和作用机制、当前治疗指南以及益生菌根除幽门螺杆菌疗效的文献。
